as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹819.55
Change
+1.95 (0.24%)
Open
₹817.0
Prev. Close
₹817.6
Day High
₹828.65
Day Low
₹811.0
Volume Analysis
Traded
152,812
Delivered
76,783
Delivery %
50.25%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Trading within 3% of its 52-week high (₹839.0)
Weaknesses (1)
- •Low return on equity (8.45%)
Opportunities (1)
- •Strong 3-year EPS growth (34.7%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹846.11 | ₹837.38 | ₹828.46 | ₹819.73 | ₹810.81 | ₹802.08 | ₹793.16 |
| Fibonacci | ₹837.38 | ₹830.64 | ₹826.47 | ₹819.73 | ₹812.99 | ₹808.82 | ₹802.08 |
| Camarilla | ₹824.4 | ₹822.79 | ₹821.17 | ₹819.73 | ₹817.93 | ₹816.31 | ₹814.7 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+83.8%
1 Week
-0.23%
1 Month
+6.08%
3 Months
+31.52%
6 Months
+65.08%
1 Year
+83.49%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹277.41
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
8.54%
Net margin 6.51% × asset turnover 0.8x × equity multiplier 1.64x
Company Overview
Sector
Healthcare
Market Cap
₹12,869 Cr
P/E (TTM)
42.2
ROE
8.45%
Book Value
₹211.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Akums Drugs And Pharma L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 64/100. The strongest factor is Financial Strength (100/100), while Valuation (29/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹839.0); low return on equity (8.45%). FII holding has been falling.
TopFund Score — Fundamentals Quality
64/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- −Stock is trading at 3.88 times its book value
- −The company has delivered a poor sales growth of 9.87% over past five years.
- −Company has a low return on equity of 9.89% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Intimation of Schedule of the Institutional Investors Meets
Akums received ESG rating of 65 for FY 2025-26 from NSE Sustainability on September 2, 2026.
Akums will attend Ashwamedh–Elara India Dialogue 2026 on 2 September 2026 in Mumbai.
Akums cancels its August 25, 2026 investor meet with Antique Stock Broking due to medical reasons.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 970 | 1,181 | 1,083 | 944 | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 |
| Expenses + | 1,095 | 1,029 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | 992 |
| Operating Profit | -125 | 152 | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 | 175 |
| OPM % | -13.0% | 13.0% | 9.0% | 0.3% | 13.0% | 12.0% | 12.0% | 9.0% | 13.0% | 9.0% | 13.0% | 13.0% | 15.0% |
| Other Income + | 8 | -21 | 10 | 10 | 7 | 17 | 19 | 26 | 27 | 32 | 16 | 34 | 30 |
| Interest | 12 | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 | 25 |
| Depreciation | 30 | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 | 41 |
| Profit before tax | -159 | 87 | 59 | -33 | 87 | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 |
| Tax % | 18.0% | 62.0% | -229.0% | 20.0% | 30.0% | 27.0% | 27.0% | -99.0% | 32.0% | 35.0% | 32.0% | 33.0% | 27.0% |
| Net Profit + | -187 | 33 | 195 | -39 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 |
| EPS in Rs | -13 | 2 | 14 | -3 | 4 | 4 | 4 | 9 | 4 | 3 | 4 | 5 | 6 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,464 | 1,651 | 2,414 | 2,723 | 3,672 | 3,655 | 4,178 | 4,118 | 4,359 | 4,502 |
| Expenses + | 1,340 | 1,507 | 2,240 | 2,485 | 3,761 | 3,361 | 4,055 | 3,654 | 3,837 | 3,934 |
| Operating Profit | 124 | 144 | 174 | 238 | -89 | 294 | 123 | 465 | 522 | 568 |
| OPM % | 8.0% | 9.0% | 7.0% | 9.0% | -2.4% | 8.0% | 3.0% | 11.0% | 12.0% | 13.0% |
| Other Income + | 6 | 6 | 26 | 11 | 7 | 15 | 8 | 69 | 108 | 112 |
| Interest | 23 | 22 | 20 | 7 | 17 | 46 | 51 | 35 | 94 | 96 |
| Depreciation | 31 | 38 | 67 | 70 | 95 | 113 | 126 | 153 | 155 | 159 |
| Profit before tax | 77 | 89 | 114 | 172 | -193 | 150 | -45 | 345 | 382 | 426 |
| Tax % | 51.0% | 50.0% | 62.0% | 28.0% | 30.0% | 35.0% | -102.0% | 0.0% | 33.0% | — |
| Net Profit + | 43 | 61 | 44 | 123 | -251 | 98 | 1 | 344 | 256 | 293 |
| EPS in Rs | 367 | 523 | 336 | 943 | -35 | 7 | 0 | 21 | 16 | 19 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 18.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Reserves | 493 | 628 | 721 | 884 | 608 | 689 | 681 | 3,016 | 3,283 |
| Borrowings + | 255 | 213 | 175 | 130 | 395 | 619 | 565 | 88 | 157 |
| Other Liabilities + | 293 | 318 | 1,140 | 1,137 | 2,033 | 1,905 | 2,229 | 960 | 1,958 |
| Total Liabilities | 1,042 | 1,161 | 2,037 | 2,152 | 3,050 | 3,241 | 3,504 | 4,095 | 5,429 |
| Fixed Assets + | 444 | 501 | 645 | 904 | 1,021 | 1,097 | 1,191 | 1,397 | 1,456 |
| CWIP | 0 | 11 | 57 | 17 | 31 | 103 | 195 | 163 | 177 |
| Investments | 0 | 18 | 6 | 20 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 598 | 632 | 1,329 | 1,212 | 1,998 | 2,041 | 2,118 | 2,535 | 3,796 |
| Total Assets | 1,042 | 1,161 | 2,037 | 2,152 | 3,050 | 3,241 | 3,504 | 4,095 | 5,429 |
| Equity Capital | 1 | 1 | 1 | 1 | 14 | 29 | 29 | 31 | 31 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 72 | 89 | 28 | 131 | 32 | 177 | 498 | 465 | 1,181 |
| Cash from Investing Activity + | -150 | -123 | -190 | -109 | -235 | -305 | -331 | -548 | -930 |
| Cash from Financing Activity + | 66 | 37 | 233 | -91 | 236 | 125 | -108 | 73 | 34 |
| Net Cash Flow | -11 | 4 | 71 | -70 | 33 | -4 | 59 | -10 | 285 |
| CFO/OP | 72 | 98 | 44 | 74 | -98 | 93 | 455 | 118 | 243 |
| Free Cash Flow | -78 | -34 | -34 | 49 | -224 | -110 | 212 | 201 | 958 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Others | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% |
| Public | 7.14% | 8.64% | 8.84% | 8.92% | 10.46% | 6.45% | 6.29% | 6.67% |
| Promoters | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% |
| FII | 7.34% | 6.36% | 5.77% | 4.24% | 2.27% | 1.14% | 1.38% | 1.91% |
| DII | 7.53% | 6.99% | 7.39% | 8.85% | 9.28% | 14.41% | 14.36% | 13.44% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Akums Drugs And Pharma L (this stock) | 12,869 | 42.2 | 3.88 | 8.45% |
| Sudeep Pharma Limited | 13,157 | 72.0 | 14.9 | 25.2% |
| Corona Remedies Limited | 13,219 | 62.3 | 17.73 | 29.5% |
| Park Medi World Limited | 12,368 | 44.5 | 6.11 | 16.8% |
| Metropolis Healthcare Ltd | 12,086 | 58.1 | 7.99 | 13.6% |
| Rainbow Childrens Med Ltd | 13,957 | 48.7 | 8.48 | 15.9% |
| Indegene Limited | 14,319 | 34.4 | 4.57 | 14.4% |
Which Mutual Funds Hold Akums Drugs And Pharma L?
Frequently Asked Questions about Akums Drugs And Pharma L
Akums Drugs And Pharma L (AKUMS) closed at ₹819.55 on NSE on 25 September 2026, up 1.95 (0.24%) from the previous close.
Akums Drugs And Pharma L trades on the NSE (National Stock Exchange of India) under the symbol AKUMS.
Akums Drugs And Pharma L has a trailing twelve-month P/E (price-to-earnings) ratio of 42.2.
Akums Drugs And Pharma L has a dividend yield of 0.12%.
Akums Drugs And Pharma L's 52-week high is ₹839.0 and its 52-week low is ₹409.0.
Akums Drugs And Pharma L has a market capitalisation of ₹12,869 crore.
Akums Drugs And Pharma L has a TopFund Quality Score of 64/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Akums Drugs And Pharma L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.